Decreased miR-455-3p promotes diabetic retinopathy progression via modulating retinal endothelial proliferation and apoptosis.

BACKGROUND

Diabetic retinopathy (DR) is one of the common ocular complications of diabetes. Recent studies have also found that miR-455-3p is dysregulated in DR. However, its underlying mechanisms warrant further investigation.

OBJECTIVE

This study focused on the clinical value of miR-455-3p and its regulatory mechanisms in DR.

MATERIALS AND METHODS

This study recruited 130 patients with DR and 105 healthy individuals. HRMECs treated with high glucose were used to simulate DR conditions. The expression of miR-455-3p and Integrin beta 1() were assessed by qRT-PCR while the target relationship between them was validated via Dual-luciferase reporter assay. ROC curve was utilized for the diagnostic performance. CCK-8 and flow cytometry were employed for proliferation and apoptosis measurement while ELISA was used for inflammation.

RESULTS

Serum miR-455-3p was found to be distinctly downregulated in patients with DR. The expression of serum miR-455-3p was negatively associated with HbA1c levels in patients with DR. The miR-455-3p also exhibited strong diagnostic potential for distinguishing patients with DR from healthy individuals. In high glucose-induced HRMECs, miR-455-3p was significantly downregulated. miR-455-3p can target and negatively regulate , thereby inhibiting the proliferation and inflammation of HRMECs induced by high glucose and promoting cell apoptosis.

CONCLUSION

Decreased miR-455-3p promotes diabetic retinopathy progression via negative regulation on .

CLINICAL TRIAL NUMBER

Not applicable.